RxSight, of Aliso Viejo, California, launched on July 30 a $118 million initial public offering of 7.35 million shares of common stock at a price of $16 per share. Shares are trading on the Nasdaq under the symbol RXST.
Harrow Health, Inc. announced that it has entered into an agreement with Sintetica to acquire the marketing and supply rights in the U.S. and Canada for AMP 100, a patented ophthalmic surgical drug candidate.
Johnson & Johnson Vision revealed new comparative clinical study findings evaluating TearScience LipiFlow treatment in cataract surgery. The data concluded that treating patients with TearScience LipiFlow prior to cataract surgery significantly reduced patient-reports of halos compared to control group (58.6 vs. 79 percent) and showed larger improvements in Meibomian Gland Score (MGD) than control group (107 vs. 66 percent).
Market Scope identified 21 ophthalmic transactions totaling nearly $1.2 billion during Q2-2021. This compares with $2.3 billion from 32 transactions in Q1-2021 and $2.3 billion from 28 transactions in Q2-2020. Funds raised included investments for the development of new products and technologies, commercialization of new products, or outright purchases of products or technologies. Transactions have ranged from $250 thousand to …
Eyenuk, of Los Angeles, announced July 20 that it had completed a financing round of $6.2 million led by investment management company AXA IM, through AXA IM Alts, with existing investors also participating.
Ocular Therapeutix has entered into a discovery collaboration with Mosaic Biosciences, of Boulder, Colorado, to identify new targets and therapeutic agents aimed at the treatment of dry age-related macular degeneration (AMD).